Detail akcie Adaptive Biotech Rg online

Business Summary: Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Adaptive Biotechnologies Corp revenues increased 56% to $205.3M. Net loss decreased 63% to $45.9M. Revenues reflect MRD segment increase of 43% to $150.4M, Immune Medicine segment increase from $26.1M to $54.8M. Lower net loss reflects Research and development - Balancing val decrease of 47% to $8.3M (expense), Impairment of long-lived assets decrease from $7.2M (expense) to $0K.